Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | CASP2 | P42575 | 1/20 | 0.72 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 3/20 | 0.60 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.55 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436704 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL10866304 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL2944555 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL3708747 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL8210316 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL1901704 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL10866272 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL8197425 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL8209020 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA | |
| SCHEMBL626501 | 1.00 | MEN1 (0.81) | MEN1KMT2ACASP2EPHX1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220722-A2 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | UNIV MICHIGAN REGENTS (US) | 2023-07-13 | — | — | US | disclosed |
| EP-3523311-B1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3756663-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | Seagen Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-9663466-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-0717742-B1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5780633-A | Process for the preparation of indolizine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5716477-A | CONSISTS OF A SUPPORT AND THERMAL IMAGE TRANSFER INK LAYER FORMED ON SAID SUPPORT CONSISTS OF A COLORING AGENT AND A PLASTICIZER FOR LOWERING MELT VISCOSITY OF THE RESIN, HIGH THERMOSENSITIVITY ON CLOTH, PLASTIC, OR PAPER RECEIVER | RICOH COMPANY, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0717742-A1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007279-A2 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-16 | — | — | WO | disclosed |
| US-5334716-A | Preventing testosteron 5a-reductase mediated diseases; alopecia, acne, prostatism | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-02 | — | — | US | disclosed |
| EP-0519353-A2 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-4575734-A | LEVCO DYES | RICOH COMPANY, LTD. (JP) | 1986-03-11 | — | — | US | disclosed |
| US-4562448-A | Heat-sensitive transfer medium | RICOH CO., LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
| US-4547788-A | SHEET HAVING LAYER CONTAINING LEVCO DYE; ACCEPTOR SHEET CONTAININGCOLORING AGENT; POROUS FILLER | RICOH COMPANY, LTD. (JP) | 1985-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | MEN1 4294/4885KMT2A 1074/4885CASP2 509/4885 |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | MEN1 3080/4885KMT2A 1861/4885CASP2 3941/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | MEN1 1906/4885KMT2A 193/4885CASP2 4168/4885 |
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | PTPN1, PTPRS, PPM1D | MEN1 1432/4885KMT2A 675/4885CASP2 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.